SCHEMBL405911

SCHEMBL405911

O=C(OCCCOCc1ccccc1)ON1C(=O)CCC1=O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NAAA Q02083 1/20 0.45
TEAD3 Q99594 2/20 0.43
CCNE1 P24864 1/20 0.41
CDK2 P24941 1/20 0.41
GSK3B P49841 1/20 0.41
ALOX12 P18054 1/20 0.40
MEN1 O00255 1/20 0.39
GAA P10253 1/20 0.39
KMT2A Q03164 1/20 0.39
EPHX2 P34913 1/20 0.39
PKM P14618 2/20 0.38
CYP2C19 P33261 2/20 0.38
ALDH1A1 P00352 2/20 0.37
CYP3A4 P08684 2/20 0.37
BCHE P06276 1/20 0.37
TSHR P16473 1/20 0.37
MAPK1 P28482 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
MGLL Q99685 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL406279 0.92 KMT2A (0.41) TEAD3CCNE1CDK2GSK3BALOX12
SCHEMBL11323517 0.84 ALDH1A1 (0.47) CCNE1CDK2GSK3BMEN1KMT2A
SCHEMBL142445 0.84 ALDH1A1 (0.47) CCNE1CDK2GSK3BMEN1KMT2A
SCHEMBL1279658 0.83 ALDH1A1 (0.46) CCNE1CDK2GSK3BMEN1KMT2A
SCHEMBL17256401 0.83 TEAD3 (0.43) NAAATEAD3ALOX12MEN1GAA
SCHEMBL6168143 0.82 HCAR2 (0.45) ALOX12PKMALDH1A1CYP3A4TSHR
SCHEMBL11527408 0.82 HTT (0.54) CCNE1CDK2GSK3BMEN1GAA
SCHEMBL13606692 0.81 ALOX12 (0.32) ALOX12SMN1; SMN2
SCHEMBL3230002 0.81 NAAA (0.52) NAAATEAD3KMT2AEPHX2ALDH1A1
SCHEMBL4702445 0.81 TDP1 (0.57) ALOX12KMT2AALDH1A1BCHEMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120065152-A1 PRODRUGS OF GUANFACINE SHIRE LLC (US) 2012-03-15 US disclosed
EP-0528661-A2 HIV protease inhibitors with N-terminal polyether substituents MERCK & CO. INC. (US) 1993-02-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120065152-A1 PRODRUGS OF GUANFACINE UGT1A6, GDA, UGT1A3 NAAA 259/4885TEAD3 3300/4885CCNE1 3273/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.